Skip to content

Role of Jatamansi as Shukrajanana in oligospermia

PHYTOCHEMICAL AND CLINICAL EVALUATION OF SHUKRAJANANA EFFECT OF JATAMANSI (NARDOSTACHYS JATAMANSI DC) WSR TO OLIGOSPERMIA

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052503
Enrollment
50
Registered
2023-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N461- Oligospermia

Interventions

None listed

Sponsors

A and U Tibbia College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age From 21 Years to 40 Years Male. 2. No history of serious illness or disease. 3. Not under any type of medical treatment since last six months. 4. Subjects having sperm count 05 to 15 million per ml. 5. Subjects who are able to come for follow up on fixed visits and are well aware about the treatment plans. 7. Subjects willing to participate and able to give written informed consent.

Exclusion criteria

Exclusion criteria: Patients having medical history of- a)Men with a total sperm count of 20 million/mL. b)Patients having a history of congenital deformity in genitals. c)Patients with evidence of Malignancy. d)Patients having any type of surgery of genitals. e)Known case of Hypertension, Diabetes Mellitus, Thyroid Dysfunction. f)Patient having any sexual transmitted diseases. g)Patients on prolonged medication with corticosteroids, antidepressants, anticholinergics, immunosuppressant, etc. or any other drugs that may have an influence on the outcome of the study. h)Patients with poorly controlled hypertension (systolic >140 and diastolic >90 mm of Hg) despite of antihypertensive agents. i)Patients who have completed participation in any other clinical trial drugs or their ingredients.

Design outcomes

Primary

MeasureTime frame
The Expected Primary End point is improvement in the sperm count from baseline (Day 0) after 90 days of therapy.Timepoint: 90 days

Secondary

MeasureTime frame
The Expected secondary outcome is the safety and efficacy of the therapy under investigation. Safety will be assessed based on the adverse events recorded during the study.Timepoint: 90 days

Countries

India

Contacts

Public ContactDr Banshidhar Behera

A and U Tibbia College and Hospital karol bagh

drbanshi@rediffmail.com9354925047

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026